A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events

• Hauptverfasser: Hua Fang (VerfasserIn), Xiequn Xu (VerfasserIn), Kulvinder Kaur (VerfasserIn), Matthew Dedek (VerfasserIn), Guang-dan Zhu (VerfasserIn), Bae J. Riley (VerfasserIn), Frank G. Espin (VerfasserIn), Andria L. Del Tredici (VerfasserIn), Tanya A. Moreno (VerfasserIn)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Purpose:HLA-B∗15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions in patients treated with carbamazepine (CBZ) and structurally related medications. FDA-approved labeling recommends HLA-B∗15:02 screening before CBZ therapy in patients of Asian ancestry. In this...